The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for ALL coinfected patients from low- to high-income settings.
作者信息
Lacombe Karine, Klein Marina B
机构信息
Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.
AP-HP, Hôpital Saint Antoine, Infectious Diseases Unit, Paris, France.
出版信息
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25073. doi: 10.1002/jia2.25073.
Abstract
摘要
相似文献
1
The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for ALL coinfected patients from low- to high-income settings.消除病毒性肝炎的崎岖之路：确保为所有来自低收入到高收入环境的合并感染患者提供抗病毒治疗。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25073. doi: 10.1002/jia2.25073.
2
Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access.第三届国际艾滋病毒/病毒性肝炎合并感染会议亮点——艾滋病毒/病毒性肝炎：改善诊断、抗病毒治疗及可及性
Hepatol Med Policy. 2017 Apr 20;2:8. doi: 10.1186/s41124-017-0025-0. eCollection 2017.
3
Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?德国国家丙型肝炎病毒（HCV）登记处登记的直接作用抗病毒（DAA）为基础的 HCV 治疗结束后 12 周持续病毒学应答率：HIV 合并感染是否会影响 DAA 联合治疗的应答？
HIV Med. 2018 Apr;19(4):299-307. doi: 10.1111/hiv.12579. Epub 2018 Jan 25.
4
Research gaps in viral hepatitis.病毒性肝炎研究中的空白。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25054. doi: 10.1002/jia2.25054.
5
Advances in treating drug-resistant hepatitis B virus in HIV-infected patients.治疗HIV感染患者耐药乙型肝炎病毒的进展。
Expert Opin Pharmacother. 2015 Feb;16(2):179-86. doi: 10.1517/14656566.2015.973852. Epub 2014 Dec 22.
6
[Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus].[西班牙艾滋病研究与治疗小组（Gesida）/西班牙儿科传染病学会（PNS）/西班牙医院传染病与卫生保健协会（AEEH）关于成人HIV与甲型、乙型和丙型肝炎病毒合并感染的管理与治疗建议]
Enferm Infecc Microbiol Clin. 2010 Jan;28(1):31.e1-31. doi: 10.1016/j.eimc.2009.12.001.
7
HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.东欧地区的艾滋病毒/肝炎合并感染以及泛欧洲预防和管理肝炎的新方法。
Int J Drug Policy. 2007 Oct;18(5):426-32. doi: 10.1016/j.drugpo.2007.01.011. Epub 2007 Feb 15.
8
Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.CD4 +血细胞计数和HIV病毒载量对HIV与HCV合并感染患者直接抗病毒药物治疗反应的影响：来自德国丙型肝炎登记处的见解
HIV Clin Trials. 2018 Dec;19(6):225-234. doi: 10.1080/15284336.2018.1538193.
9
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.对HIV/丙型肝炎病毒合并感染患者进行无干扰素的丙型肝炎病毒治疗可导致血清低密度脂蛋白浓度升高。
AIDS Res Hum Retroviruses. 2016 May;32(5):456-62. doi: 10.1089/AID.2015.0170. Epub 2015 Dec 15.
10
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.来自科特迪瓦的接受治疗的HIV-HBV合并感染患者中，拉米夫定耐药性乙肝病毒和肝脏炎症发作的风险较低。
Antivir Ther. 2015;20(6):643-54. doi: 10.3851/IMP2959. Epub 2015 Apr 8.
本文引用的文献
1
Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.在中低收入国家和地区，治疗倡导者采取策略扩大艾滋病毒和丙型肝炎病毒抗病毒治疗的可及性：确保不落下任何人。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25060. doi: 10.1002/jia2.25060.
2
Research gaps in viral hepatitis.病毒性肝炎研究中的空白。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25054. doi: 10.1002/jia2.25054.
3
Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.Hep-CORE：2016 年和 2017 年 25 个欧洲国家的患者群体报告的病毒性肝炎政策环境的横断面研究。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25052. doi: 10.1002/jia2.25052.
4
Approaches for simplified HCV diagnostic algorithms.简化 HCV 诊断算法的方法。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25058. doi: 10.1002/jia2.25058.
5
Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?在 HIV 感染者中实现丙型肝炎病毒消除是否可行？以及需要采取哪些措施来实现这一目标？
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25062. doi: 10.1002/jia2.25062.
6
Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.丙型肝炎病毒感染人群中丙型肝炎病毒护理的关联和保留：直接作用抗病毒药物时代的早期数据。
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25051. doi: 10.1002/jia2.25051.
7
What do clinicians need to watch for with direct-acting antiviral therapy?临床医生在使用直接作用抗病毒药物治疗时需要注意什么？
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25076. doi: 10.1002/jia2.25076.
8
How far are we from viral hepatitis elimination service coverage targets?我们距离实现病毒性肝炎消除服务覆盖目标还有多远？
J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25050. doi: 10.1002/jia2.25050.
9
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.1990年至2013年病毒性肝炎的全球负担：全球疾病负担研究2013的结果。
Lancet. 2016 Sep 10;388(10049):1081-1088. doi: 10.1016/S0140-6736(16)30579-7. Epub 2016 Jul 7.
10
Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.HIV 感染者中 HCV 合并感染的流行率和负担：一项全球系统评价和荟萃分析。
Lancet Infect Dis. 2016 Jul;16(7):797-808. doi: 10.1016/S1473-3099(15)00485-5. Epub 2016 Feb 25.
Zotero 插件